CD38 and Miyoshi myopathy: CRISPR‐Cas9 has been applied to primary NK cells to disrupt the CD38 gene, with the goal of averting NK cell fratricide when used in conjunction with daratumumab (anti‐CD38) in view of the fact that CD38 is expressed on NK cells as well as on tumour cells from multiple myeloma (MM) and acute myeloid leukaemia (AML) [68].